Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials

MLA

Daniel F. Martin, et al. “Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.” Ophthalmology Retina, vol. 5, Oct. 2021, pp. 962–74. EBSCOhost, https://doi.org/10.1016/j.oret.2021.06.003.

APA

Daniel F. Martin, Juan E. Grunwald, Gui-Shuang Ying, Maureen G. Maguire, Maxwell Pistilli, Glenn J. Jaffe, Peiying Hua, Cynthia A. Toth, Jason Q. Core, & Ebenezer Daniel. (2021). Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology Retina, 5, 962–974. https://doi.org/10.1016/j.oret.2021.06.003

Chicago

Daniel F. Martin, Juan E. Grunwald, Gui-Shuang Ying, Maureen G. Maguire, Maxwell Pistilli, Glenn J. Jaffe, Peiying Hua, Cynthia A. Toth, Jason Q. Core, and Ebenezer Daniel. 2021. “Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.” Ophthalmology Retina 5 (October): 962–74. doi:10.1016/j.oret.2021.06.003.